Themis Bioscience themisbio.com


Public lists: Pharma Startups (4733)

Themis Bioscience develops prophylactic vaccines with a focus on emerging tropical infectious diseases and has initial vaccine candidates currently in development for chikungunya and dengue fever. The company has exclusive, worldwide licenses for chikungunya- and dengue vaccines, based on the innovative and fully patent-protected measles virus vaccine vector platform from the Institut Pasteur in Paris. This platform underpins Themis' growing pipeline of vaccines. Themis and Institut Pasteur are ...Show all

Themis Bioscience develops prophylactic vaccines with a focus on emerging tropical infectious diseases and has initial vaccine candidates currently in development for chikungunya and dengue fever. The company has exclusive, worldwide licenses for chi...Show all

Company (Alive / Active)

Phone: +43 1 236 7151

Fax:

Muthgasse 11/2

Vienna, 1190
Austria

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Themis Bioscience $35.8M Jan 4, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Themis Bioscience Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Omnes CapitalPrivate EquityParis, FranceSeries C, Series B - II, Series B, Series A
Innovate UKGovernmentWiltshire, England, United KingdomGrant - II, Grant
Austria WirtschaftsserviceBankWien, AustriaSeed
AWS GrunderfondsVenture CapitalVienna, AustriaSeries C, Series B - II
Global Health Investment FundAsset/Investment ManagementNew York, New York, United StatesSeries C
See all 8 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Recombinant measles virus expressing chikungunya virus polypeptides and their applications Sep 26, 2013 May 23, 2017 Patent